Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Steven J. Nicol"'
Autor:
Steven J. Nicol, Xinyue Liu, Lisa M. Hess, Yajun Zhu, Viviana Garcia-Horton, Jasmina I. Ivanova, Sophia Graham
Publikováno v:
The patient. 12(4)
There has been no single standard-of-care treatment of patients with advanced/metastatic soft tissue sarcoma (STS). This study was designed to understand patient and oncologist preferences in the advanced/metastatic setting. Adult patients diagnosed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::651660452977400dee31b7ea62c8dcdd
https://pubmed.ncbi.nlm.nih.gov/30659513
https://pubmed.ncbi.nlm.nih.gov/30659513
Autor:
Sean D. Candrilli, Lisa M. Hess, James A. Kaye, Maria J. Lorenzo, Steven J. Nicol, Rohan Parikh
Publikováno v:
Clinical Sarcoma Research
Clinical Sarcoma Research, Vol 8, Iss 1, Pp 1-16 (2018)
Clinical Sarcoma Research, Vol 8, Iss 1, Pp 1-16 (2018)
Background To describe patient and tumor characteristics, treatments, and survival among older adults in the United States with advanced soft-tissue sarcoma (STS), across and by categories of specifically defined histologic subtypes. Methods We condu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21c2f4d2f66130dd1fb485b3fb06e3b5
https://pubmed.ncbi.nlm.nih.gov/29744029
https://pubmed.ncbi.nlm.nih.gov/29744029
Autor:
Li Li, Steven J. Nicol, Robert Sedgley, Pamela Landsman-Blumberg, Veena Shankaran, Gebra Cuyun Carter, Barbara H. Johnson
Publikováno v:
Clinical Colorectal Cancer. 13:178-184
Introduction In 2008, the National Comprehensive Cancer Network guidelines were revised in light of the identification of the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene as a biomarker of nonresponse to epidermal growth factor receptor inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::135776817f3b115b3db59d320c43aefa
https://doi.org/10.1016/j.clcc.2014.05.001
https://doi.org/10.1016/j.clcc.2014.05.001
Autor:
Sabine Ermisch, Ting Wang, Michael A. Carducci, Jeannette Day, Deborah K. Armstrong, Lori Kornberg, Rodney Decker, Connie Collins, Steven J. Nicol, Donald Thornton, Lee P. Resta, Zhe Zhang, Nwabundo Nwankwo
Publikováno v:
Investigational New Drugs
Summary Purpose Given distinct mechanism of actions of enzastaurin and bevacizumab, preclinical studies suggest enhanced antitumor activity in combination. This phase I study assessed the combination’s safety and efficacy. Patients and methods Six
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::472eebf5ca200034f61e7d9df3fcb0b9
https://doi.org/10.1007/s10637-012-9850-6
https://doi.org/10.1007/s10637-012-9850-6
Autor:
Clemens Stoffregen, Robert A. Wolff, Anwar Hossain, Martin Fuchs, Steven J. Nicol, Maria Di Bartolomeo, Volker Heinemann
Publikováno v:
Cancer. 118:4132-4138
BACKGROUND: Enzastaurin and bevacizumab have demonstrated synergistic antitumor effects and, in phase 1 studies, the combination was well tolerated. This phase 2 study assessed enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab as maintenanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f90b776e69f40f9fec6c290dead2945
https://doi.org/10.1002/cncr.26692
https://doi.org/10.1002/cncr.26692
Autor:
Patricia Hentschel, John F. Gill, Paul S. Ritch, Sandeep K. Malik, C. G. Leichman, Stefan Madajewicz, Donald J. Higby, M Qaseem Khan, Luping Zhao, David M. Waterhouse, Steven J. Nicol
Publikováno v:
Investigational New Drugs. 30:772-778
Purpose To assess safety and efficacy of folinic acid, 5-fluorouracil, gemcitabine (FFG) and folinic acid, fluorouracil, oxaliplatin (FOLFOX4) regimens with added bevacizumab as first-line treatment in patients with advanced colorectal cancer (CRC).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a34b1e1956970bb8eff39caf98e38a2
https://doi.org/10.1007/s10637-010-9598-9
https://doi.org/10.1007/s10637-010-9598-9
Autor:
Carlos Becerra, Lalan S. Wilfong, Kristi A. Boehm, Scott P. Myrand, Donald A. Richards, Rebecca R. Hozak, Lina Asmar, John F. Gill, Luping Zhao, Feng Zhan, Steven J. Nicol, Paul R. Kuefler, Robert H. Gersh, Coleman K. Obasaju, Brian Mullaney
Publikováno v:
Investigational New Drugs. 29:144-153
Purpose Gemcitabine (G) is standard therapy for pancreatic cancer. Enzastaurin (E) inhibits PKCβ and PI3K/AKT signaling pathways with a dose-dependent effect on growth of pancreatic carcinoma xenografts. Data suggest that the GE combination may impr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b50e4982b7e6d9c33359c285aa0cc910
https://doi.org/10.1007/s10637-009-9307-8
https://doi.org/10.1007/s10637-009-9307-8
Autor:
Timothy J. Kinsella, Mark M. Zalupski, John F. Gill, Andre Konski, John P. Hoffman, Rong M. Xu, Jordan Berlin, Philip A. Philip, Al B. Benson, Theodore S. Lawrence, Mary F. Mulcahy, Cornelius J. McGinn, Nipun B. Merchant, Steven J. Nicol, Mark S. Talamonti, William Small, A. Bapsi Chakravarthy, Gary M. Freedman
Publikováno v:
Journal of Clinical Oncology. 26:942-947
PurposeGemcitabine is effective in the treatment of pancreatic cancer and is a potent radiosensitizer. This study assessed safety and efficacy of full-dose gemcitabine administered before and during concurrent three-dimensional conformal radiation (3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caa6311f8f7979a89ae856c457060090
https://doi.org/10.1200/jco.2007.13.9014
https://doi.org/10.1200/jco.2007.13.9014
Autor:
Svetislava J. Vukelja, Robert L. Ruxer, Daniel Atienza, Thomas E. Hutson, Thomas F. Gregory, Robert Delaune, Robert N. Raju, Philip Y. Dien, William R. Berry, Margaret Deutsch, Joseph J. Muscato, Stephanie Mull, Steven J. Nicol, Sanjay Awasthi, Karen Hood, Des Ilegbodu, Michael J. Kolodziej
Publikováno v:
Investigational New Drugs. 26:151-158
Objectives: Gemcitabine (G) plus cisplatin (C) is standard care for metastatic transitional cell carcinoma (TCC) of the urothelium. Pemetrexed (P), alone or in combination with G, is active in metastatic TCC. However, the safety and efficacy of P com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6ab5008d0a8b4dbf3277b37b0461bde
https://doi.org/10.1007/s10637-007-9111-2
https://doi.org/10.1007/s10637-007-9111-2
Autor:
Michelle R. Mahoney, Richard M. Goldberg, Michael K. Gornet, Joseph Rubin, Matthew P. Goetz, Matthew M. Ames, George P. Kim, Steven R. Alberts, Steven J. Nicol, Richard M. Weinshilboum
Publikováno v:
Clinical Colorectal Cancer. 6:572-577
Purpose Pemetrexed, an antifolate involved in purine and pyrimidine formation, is a potential alternative to fluoropyrimidines in the treatment of colorectal cancer. A phase I trial was performed to establish the maximum tolerated dose (MTD) of pemet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9526dc5615db671e4cb0982f55f9c395
https://doi.org/10.3816/ccc.2007.n.024
https://doi.org/10.3816/ccc.2007.n.024